References in periodicals archive ?
The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
Results: Twenty five cases of anaplastic large cell lymphoma were reported during this time period.
Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of route of administration and molecule type.
Anaplastic Large Cell Lymphoma (ALCL) in Women with Breast Implants: Preliminary FDA Findings and Analyses: Center for Devices and Radiological Health US Food and Drug Administration, January 2011:1-13.
Anaplastic large cell lymphoma with florid granulomatous reaction - A case report and review of literature.
Researchers at Rand Corporation said that a systematic review of the literature has led them to conclude that anaplastic large cell lymphoma may be associated with breast implants, but that it is a less-aggressive form of the disease.
The Food and Drug Administration is asking health care professionals to report any confirmed cases of anaplastic large cell lymphoma (ALCL) in women with silicone gel- or saline-filled breast implants, citing concerns about a possible association.
Washington, Jan 27 (ANI): Women with saline and silicone gel-filled breast implants may be at greater risk of developing a rare form of blood cancer known as anaplastic large cell lymphoma (ALCL), according to the US Food and Drug Administration.
All the patients had anaplastic large cell lymphoma that had recurred or not responded to previous treatment.
In the survival analysis by PTCL subtype, PTCL-unspecified (PTCL-U) cases had the longest median survival at 9 months, followed by anaplastic large cell lymphoma (ALCL) at 6 months and primary CNS lymphoma (PCNSL) at 2.
Treatment with SGN-35 resulted in complete tumor regressions in preclinical models of Hodgkin's disease and anaplastic large cell lymphoma (ALCL).
A biopsy of the lesion demonstrated an anaplastic large cell lymphoma (ALCL).
Ki-l-positive anaplastic large cell lymphoma of the masticator space with intracranial extension.
Takeda will present on a wide range of topics, including full data from the Phase 3 ALCANZA study of ADCETRIS in CD30-positive cutaneous T-cell lymphoma, as well as 5-year overall survival data for the pivotal Phase 2 study of ADCETRIS in systemic Anaplastic Large Cell Lymphoma (sALCL) in partnership with Seattle Genetics for the first time.